Key Highlights

  • Medpace Holdings reported second-quarter revenue of $707.3 million, a 17.2% increase from the previous year.
  • New business awards rose to $795.7 million, reflecting strong demand in the market.
  • Shares are up 15.9% over the past month, although they remain down 7.5% year-to-date.

Medpace Holdings, Inc. (NASDAQ: MEDP) has reported a notable second-quarter performance, with revenue climbing to $707.3 million, marking a 17.2% increase compared to $603.3 million in the same quarter last year. This growth aligns with a net earnings per share of $4.25, surpassing the consensus estimate of $4.05. The surge in revenue reflects not only Medpace's solid operational execution but also the company's ability to convert its backlog effectively into realized revenue.

Such performance is significant for investors evaluating Medpace's strong growth trajectory in the current competitive environment.

Revenue Details

In the second quarter ended June 30, 2026, Medpace's revenue increase was driven by a strong backlog conversion rate. The company's backlog rose by 4.9% year-over-year, reaching $3,014.2 million, indicative of its sustained demand for clinical development services. Net new business awards for the quarter were $795.7 million, representing an impressive 28.2% surge compared to the prior-year figure of $620.5 million.

These figures underscore Medpace's capacity to attract new contracts while effectively managing existing projects, creating a solid foundation for upcoming growth.

Financial Performance Signals

Medpace's net income for the quarter surged to $121.4 million, compared to $90.3 million in the previous year, yielding a net income margin of 17.2%. This growth was supported by an EBITDA of $153.4 million, whose margin remained steady. With total direct costs rising to $505.7 million, reflecting operational investments, the sale of services has clearly resonated well with clients.

Despite the backdrop of a contracting market, Medpace's performance illustrates a strong relative position. This influx of new awards and increased revenue signals the firm’s competitive edge and strategic positioning within the healthcare research sector.

Market Performance Context

Currently trading at a strong value, Medpace shares are experiencing a resurgence, up 15.9% over the past month, though they have declined 7.5% so far this year. This uptick in share price follows the strong quarterly results, suggesting a positive investor sentiment building around the company's future outlook. In a challenging market environment, Medpace's ability to report strong growth figures and exceed analyst expectations portrays investor confidence in its ongoing operational strategy and market execution.

Upcoming Milestones

Investors should keep an eye on Medpace's guidance for the year, forecasting revenue between $2.805 billion and $2.885 billion, reflecting anticipated growth of 10.9% to 14.0% year-over-year. The company's upcoming earnings conference call, scheduled for July 23, 2026, presents a critical opportunity for management to elaborate on growth strategies and operational efficiencies that could further enhance shareholder value. With a strong cash flow generation capability evidenced by $502.7 million in cash and cash equivalents, Medpace is well poised to continue its trajectory while pursuing potential share repurchases as part of their strategic financial management.

Based on the company's Q2 results released July 22, 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.